MicroPort NeuroTech™ Completes First Implantation of Numen™ Coil Embolization System in the U.S.

Boston, United States/Shanghai, China, 28 June 2022 - MicroPort Neurotech Limited (“MicroPort NeuroTech™”), a pioneering Chinese company in the field of neurovascular interventional treatment, today announced it has successfully completed the first commercial implantation with its independently developed Numen™ Coil Embolization System (“Numen™”) in the United States.

The procedure, which was led by Dr. Ajit S. Puri and Dr. Anna Luisa Kuhn from UMASS Memorial Health in Worcester, MA, was performed on a male patient in his mid 50’s. The surgical team deployed a total of 6 Numen™ coils through transvenous pathway, all of which detached perfectly in the procedure. The physicians noted that the coil “felt great – pushed really nicely” and “the reliability from shape to detachment is exactly what we are looking for when choosing a coil”. The implantation was supported locally by MicroPort NeuroTech™’s associated company Rapid Medical Ltd..

As a new generation of electronically detachable coils, Numen™ are made of thin and soft platinum tungsten alloy wires, which are deployed through a microcatheter when placed in the aneurysm sac. It permits stable framing, smooth filling and finishing, with superb conformability to shapes of aneurysms. Its three model series, MicroFrame, MicroFill and MicroFinish, have 177 specifications with different diameters, lengths and softness levels, providing physicians with a full range of embolization options to ensure the safety and efficacy in all stages of the coiling procedure.

Numen™, together with NumenFR Coil Detachment System was approved and commercialized in China in September 2020. It has also obtained FDA approval, CE Marking in the European Union, MFDS (Ministry of Food and Drug Safety) approval in South Korea, and ANVISA (The Brazilian Health Surveillance Agency) approval. The first overseas coil embolization procedure with Numen™ was completed in August 2021. The Numen Silk™ 3D Electronically Detachable Coil obtained NMPA in February 2022, further enriches MicroPort NeuroTech™’s portfolio of products in the field of hemorrhagic stroke and provides an additional safe and effective clinical option for physicians and patients around the world.

MicroPort NeuroTech™ became the largest shareholder of Rapid Medical in May 2021. Two companies are complementary in terms of product portfolios and global resources. As part of the cooperation, Rapid Medical acts as the exclusive distributor of MicroPort NeuroTech™’s flagship products including Numen™ in the United States, to market, promote, distribute and sell Numen™ through its sales network locally.

“The first implantation of Numen™ in the U.S. is a key step for the Company to enter the U.S. market.” Commenting on the news, Mr. Bruce Wang, Executive Director and Executive Vice President of MicroPort NeuroTech™ stated, “It also marks a deepening cooperation between MicroPort NeuroTech™ and Rapid Medical. We cannot wait to work closely with Rapid Medical and make our innovative products more diversified and accessible, to benefit more international patients.”

Mr. Zhiyong Xie, Executive Director and President of MicroPort NeuroTech™, stated, “The successful surgery strengthened our confidence to further expand our global presence. The U.S. market is not only one of the most important markets globally, but also playing an increasingly important role in our R&D and academic collaboration. MicroPort NeuroTech™ will continue to follow our brand ideology of ‘The Patient Always Comes First’ and strive to provide more premium solutions to treat neurovascular diseases for patients and doctors around the world. ”

About MicroPort NeuroTech™

Founded in Shanghai in 2012, MicroPort NeuroTech Limited (“MicroPort NeuroTech™”), a subsidiary of MicroPort Scientific Corporation (“MicroPort®”, Stock code: 00853.HK), is a pioneer and largest Chinese company in the neuro-interventional medical device industry in China, dedicated to providing innovative solutions for physicians and patients. Currently, gradually gaining access for our products into the top 10 countries in terms of neurointerventional procedures, including the United States, Japan, South Korea and Brazil. MicroPort NeuroTech™ has been gradually entered the top 10 countries and regions for the number of neurointerventional surgeries, including the United States, Europe, South Korea and Brazil. In the future, MicroPort NeuroTech™ will invest more resources in innovation and development to provide more high-quality and innovative solutions for cerebrovascular and neuro interventions for doctors and patients.

More information is available at www.medneurotech.com.

About Rapid Medical

Rapid Medical Ltd. (“Rapid Medical”) develops the premier, responsive interventional devices for neurovascular diseases such as ischemic and hemorrhagic stroke. Utilizing novel manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the intravascular environment and have greater control over procedural outcomes. TIGERTRIEVER™17 and 21, COMANECI™, and COLUMBUS™/DRIVEWIRE are CE marked and FDA cleared. TIGERTRIEVER™13 and XL are also CE marked.

More information is available at www.rapid-medical.com.